Here are four things to know:
1. Researchers conducted two randomized, controlled trials in which 28 case-series studies and five case reports were included.
2. Fecal microbiota transplantation was successful in 85 percent of recurrent CDI studies.
3. Fecal microbiota transplantation may have a substantial effect with few short-term adverse events for recurrent CDI, study authors concluded.
4. However, evidence is insufficient on fecal microbiota transplantation for refractory or initial CDI treatment, they note.
More articles on GI/endoscopy:
Dr. Richard Smith of Asheville Gastroenterology Associates to retire: 5 key notes
Ironwood Pharmaceuticals reports Q1 activity — 4 key updates
FDA holds further enrollment in GI Dynamics’ ENDO Trial: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
